Rhumbline Advisers lifted its holdings in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 3.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 43,296 shares of the biopharmaceutical company’s stock after purchasing an additional 1,455 shares during the period. Rhumbline Advisers owned about 0.10% of Intra-Cellular Therapies worth $538,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ITCI. FMR LLC boosted its holdings in shares of Intra-Cellular Therapies by 0.3% in the first quarter. FMR LLC now owns 6,511,541 shares of the biopharmaceutical company’s stock worth $105,813,000 after buying an additional 21,305 shares during the last quarter. Vanguard Group Inc. increased its holdings in Intra-Cellular Therapies by 7.3% during the first quarter. Vanguard Group Inc. now owns 2,741,887 shares of the biopharmaceutical company’s stock valued at $44,556,000 after buying an additional 186,165 shares during the last quarter. Clough Capital Partners L P increased its holdings in Intra-Cellular Therapies by 157.0% during the first quarter. Clough Capital Partners L P now owns 898,750 shares of the biopharmaceutical company’s stock valued at $14,605,000 after buying an additional 549,100 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in Intra-Cellular Therapies by 20.9% during the second quarter. DekaBank Deutsche Girozentrale now owns 289,200 shares of the biopharmaceutical company’s stock valued at $3,667,000 after buying an additional 50,000 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Intra-Cellular Therapies during the first quarter valued at approximately $4,485,000. Hedge funds and other institutional investors own 71.79% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Rhumbline Advisers Acquires 1,455 Shares of Intra-Cellular Therapies Inc. (ITCI)” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/rhumbline-advisers-acquires-1455-shares-of-intra-cellular-therapies-inc-itci/1604457.html.

Several research analysts have weighed in on ITCI shares. BidaskClub downgraded shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. SunTrust Banks, Inc. reiterated a “hold” rating and set a $22.00 price target (up previously from $16.00) on shares of Intra-Cellular Therapies in a research note on Friday, September 8th. ValuEngine raised shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Leerink Swann reissued a “market perform” rating and set a $12.00 price objective on shares of Intra-Cellular Therapies in a research report on Tuesday, August 15th. Finally, Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Tuesday, August 15th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. Intra-Cellular Therapies currently has a consensus rating of “Hold” and an average target price of $24.38.

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) opened at 15.51 on Tuesday. Intra-Cellular Therapies Inc. has a one year low of $7.85 and a one year high of $22.67. The stock’s market cap is $673.51 million. The firm’s 50-day moving average is $17.04 and its 200 day moving average is $13.33.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.33. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.03 million. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. Intra-Cellular Therapies’s revenue for the quarter was down 52.2% compared to the same quarter last year. During the same period last year, the company earned ($0.71) earnings per share. On average, analysts anticipate that Intra-Cellular Therapies Inc. will post ($2.36) EPS for the current fiscal year.

Intra-Cellular Therapies Profile

ITI Inc is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.